A Prescription for Improving Drug Formulary Decision Making
article has not abstract
Vyšlo v časopise:
A Prescription for Improving Drug Formulary Decision Making. PLoS Med 9(5): e32767. doi:10.1371/journal.pmed.1001220
Kategorie:
Policy Forum
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1001220
Souhrn
article has not abstract
Zdroje
1. LaingRWaningBGrayAFordNHoenE 2003 25 years of the WHO essential medicines lists: progress and challenges. Lancet 361 1723 1729
2. TylerLSColeSWMayJRMillaresMValentinoMA 2008 ASHP guidelines on the pharmacy and therapeutics committee and the formulary system. Am J Health Syst Pharm 65 1272 1283
3. Durán-GarcíaESantos-RamosBPuigventos-LatorreFOrtegaA 2011 Literature review on the structure and operation of Pharmacy and Therapeutics Committees. Int J Clin Pharm 33 475 483
4. TierneyMMannsB 2008 Optimizing the use of prescription drugs in Canada through the Common Drug Review. CMAJ 178 432 435
5. OuachiZAllenetBChouchaneNCalopJ 2011 Organisation of the formulary decision-making process at the hospital level: review of the international literature. Pharmacien Hospitalier et Clinicien 46 263 272
6. GalliniAJuillard-CondatBSauxM-CTabouletF 2011 Drug selection in French university hospitals: analysis of formularies for nine competitive pharmacological classes. Br J Clin Pharmacol 72 823 831
7. HollowayK 2003 Drug and therapeutics committees: a practical guide Geneva World Health Organization. Department of Essential Drugs and Medicines Policy
8. SimonGEPstatyBMMoraM 2005 Principles for evidence-based drug formulary policy. J Gen Intern Med 20 964 968
9. RuckerTD 1982 Formularies: principles, problems, and prognosis. Hosp Pharm 17 460 461
10. GlassmanPAGoodCBKelleyMEBradleyMValentinoM 2001 Physician perceptions of a national formulary. Am J Manag Care 7 241 251
11. BlumenthalDHerdmanR 2000 Description and analysis of the VA National Formulary Washington (D.C.) VA Pharmacy Formulary Analysis Committee, Division of Health Care Services National Academy Press
12. ShrankWHEttnerSLGlassmanPAschSM 2004 A bitter pill: formulary variability and the challenge to prescribing physicians. J Am Board Fam Pract 17 401 407
13. RuckerTDSchiffG 1990 Drug formularies: myths-in-formation. Med Care 28 928 942
14. BruzekRJDullingerD 1992 Drug formulary: the cornerstone of a managed pharmacy program. Journal of Pharmacy Practice 5 75 81
15. RosenauPVLalLSGlasserJH 2009 U.S. pharmacy policy: a public health perspective on safety and cost. Soc Work Public Health 24 543 567
16. TriceSDevineJMistryHMooreELintonA 2009 Formulary management in the Department of Defense. J Manag Care Pharm 15 133 146
17. AveryAJWalkerBHeronTTeasdaleSJ 1997 Do prescribing formularies help GPs prescribe from a narrower range of drugs? A controlled trial of the introduction of prescribing formularies for NSAIDs. Br J Gen Pract 47 810 814
18. MoraMW 2010 How P&T committees can be effective change agents: part 1. Am J Pharm Benefits 2 99 100
19. ShrankWH 2009 Change we can believe in: requiring better evidence for formulary coverage. Am J Pharm Benefits 1 134 136
20. RuckerTD 1999 A public-policy strategy for drug formularies: preparation or procrastination? Am J Health Syst Pharm 56 2338 2342
21. ChrenMMLandefeldCS 1994 Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA 271 684 689
22. The Special Committee of Attorneys General 2009 The Consumer & Prescriber Grant Program. Available: http://www.consumerprescribergrantprogram.org/. Accessed 18 April 2012
23. Centers for Education & Research on Therapeutics (CERTs). Available: http://certs.hhs.gov/. Accessed 25 February 2012
24. GrissingerM 2008 The truth about hospital formularies, part 1: we've come a long way—or have we? P T 33 441
25. GrissingerM 2008 The truth about hospital formularies, part 2: survey shows many myths still exist years later. P T 33 504 510
26. Institute of Medicine 2009 Initial national priorities for comparative effectiveness. research report brief Washington (D.C.) National Academy Press
27. SchneeweissS 2007 Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther 82 143 156
28. SchiffGDGalanterWL 2009 Promoting more conservative prescribing. JAMA 301 865 867
29. SchiffGDGalanterWLDuhigJLodolceAEKoronkowskiMJ 2011 Principles of conservative prescribing. Arch Intern Med 171 1433 1440
30. FuldaTRWertheimerAI 2007 Handbook of pharmaceutical public policy Binghampton (New York) Hayward Press
31. ShrankWHAschSMAdamsJSetodjiCKerrEA 2006 The quality of pharmacologic care for adults in the United States. Med Care 44 936 945
32. Foundation for Managed Care Pharmacy 2009 AMCP Format for Formulary Submissions Ver 3.0. October 2009. Available: http://www.amcp.org/FmcpCategory.aspx?id=9166. Accessed 18 April 2012
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2012 Číslo 5
- Statinová intolerance
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- DESATORO PRE PRAX: Aktuálne odporúčanie ESPEN pre nutričný manažment u pacientov s COVID-19
- Metamizol v liečbe pooperačnej bolesti u detí do 6 rokov veku
- Co dělat při intoleranci statinů?
Najčítanejšie v tomto čísle
- A Prescription for Improving Drug Formulary Decision Making
- Does Development Assistance for Health Really Displace Government Health Spending? Reassessing the Evidence
- Pregnancy and Infant Outcomes among HIV-Infected Women Taking Long-Term ART with and without Tenofovir in the DART Trial
- Criminal Justice Reform as HIV and TB Prevention in African Prisons